Xyall, an Eindhoven-based MedTech startup providing an automatic tissue dissection resolution designed to help molecular pathology workflows, has secured an funding of €7.6 million to globally roll out its molecular pathology laboratory options.
The funding was secured from a consortium led by Capricorn Companions through their Capricorn Healthtech Fund II, alongside present buyers Sioux Applied sciences, Brabant Growth Company (BOM), Well being Funding Companions, and several other non-public buyers.
Guido du Pree, CEO of Xyall, commented, “Over the previous decade, PCR and next-generation sequencing applied sciences have superior quickly. Nonetheless, the essential step of choosing tumour tissue for molecular evaluation has remained largely guide, subjective, and imprecise. With our totally automated tissue dissection options, Xyall supplies the lacking hyperlink between morphological and molecular diagnostics.”
Based in 2018 by Guido du Pree and Hans van Wijngaarden, Xyall digitises and automates the tissue dissection workflow to assist pathologists get hold of extra dependable molecular diagnostic take a look at outcomes.
Dick Sietses, Funding Associate at Capricorn Companions, mentioned, “Xyall permits pathology labs to function extra effectively, and the proof exhibits that it additionally helps extra correct diagnoses — significantly in fields like oncology the place personalised remedy plans are important.”
In response to the corporate, tissue dissection stays a largely guide and labour-intensive course of, counting on subjective evaluation and carrying a big threat of error and cross-contamination.
Xyall explains that in present medical follow, pathologists manually mark Areas of Curiosity (ROIs) on hematoxylin and eosin (H&E) stained slides. Laboratory technicians then visually translate these markings to dissection slides, manually scraping the tissue and accumulating it for downstream evaluation. The Dutch startup notes that this workflow is time-consuming, tough to scale, and additional constrained by a world scarcity of laboratory technicians.
Xyall claims to remodel this essential workflow step by combining high-resolution slide imaging, exact picture registration, workflow optimisation, and high-precision robotics into a completely automated resolution. In response to the corporate, its Automated Tissue Dissection resolution permits correct ROI dedication and dissection, reduces the workload of lab technicians, permits sooner case processing, and eliminates the danger of cross-contamination.
The corporate’s first resolution, the Tissector Excessive Throughput System, was launched in 2021 and is designed for giant molecular laboratories. It’s superb for high-volume molecular diagnostics and may maintain 1,800 slides and dissect over 80 slides per hour with an accuracy of higher than 0.1 mm. It could run for 3 hours unattended.
Later, in 2023, Xyall launched its compact Tissector Desk High (TT) resolution, which is designed for the workload of small to medium-sized molecular pathology laboratories. It could maintain 72 slides, dissect over 30 slides per hour with an accuracy of ≤ 0.1 mm, and may run for greater than 2 hours uninterrupted.
With this funding, the corporate goals to help the worldwide rollout of its Tissector Desk High, an automatic tissue dissection system. Xyall notes that Tissector TableTop is already in use at greater than 15 molecular pathology laboratories, together with laboratories in tier-1 industrial, tutorial, pharma and analysis institutes in the US.
“Molecular diagnostics play a key function in figuring out probably the most acceptable remedy, significantly in oncology. Laboratories are beneath rising strain to ship outcomes sooner and extra precisely, whereas going through a world scarcity of specialized workers. The truth that the Tissector Desk High is already deployed in additional than fifteen high-standing laboratories confirms that we’re addressing an actual and pressing want,” added Du Pree.
